论文部分内容阅读
目前已有一些关于抗病毒药物(包括苏拉明、三氮唑核苷、HPA-23、α-干扰素、甲膦酸盐及S-化合物等)在体外或体内试验中对LAV/HTLV-Ⅲ病毒复制有影响的研究报道。现分述如下: 1.苏拉明(Suramin) 以往苏拉明是治疗盘尾丝虫病和锥虫病的药物。自1979年以来,已知苏拉明具有抗逆转录酶活性及某些抗病毒活性的作用。Mitsuya等(1984年)报告,浓度为100mg/L的苏拉明可抑制LAV/HTLV-Ⅲ逆转录酶活性和H9细胞的感染。虽然在此血药浓度范围常有一些毒性效应(如肾损伤),但苏拉明的血药浓度半衰期长(约40天),可采用每周给药进行治疗。Broder等(1985年)报告,在一初步的无对照试验中,给10名爱滋病和爱滋病相关综合征患者使用了>
At present, there are some reports on the effect of antiviral drugs (including suramin, ribavirin, HPA-23, alpha-interferon, phosphonate and S-compounds etc.) on LAV / HTLV- Ⅲ virus replication influential research reports. Are as follows: 1. Suramin Suramin in the past is the treatment of onchocerciasis and trypanosomiasis drugs. Suramin has been known to have anti-retroviral activity and some antiviral activity since 1979. Mitsuya et al. (1984) reported that suramin at a concentration of 100 mg / L inhibits LAV / HTLV-III reverse transcriptase activity and H9 cell infection. Although there are often some toxic effects (such as kidney damage) at this plasma concentration range, the median serum concentration of suramin is long (about 40 days) and can be treated weekly. Broder et al. (1985) reported that in an initial uncontrolled trial, 10 patients with AIDS and AIDS-related syndrome were used>